Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.70 USD
Change Today +0.0149 / 2.18%
Volume 962.3K
VICL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VICL) Snapshot

Open
$0.69
Previous Close
$0.69
Day High
$0.70
Day Low
$0.66
52 Week High
06/12/15 - $1.55
52 Week Low
07/2/15 - $0.66
Market Cap
64.0M
Average Volume 10 Days
2.4M
EPS TTM
$-0.19
Shares Outstanding
91.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VICAL INC (VICL)

vical inc (VICL) Related Bloomberg News

View More Bloomberg News

vical inc (VICL) Related Businessweek News

No Related Businessweek News Found

vical inc (VICL) Details

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 02/26/15
Founded in 1987

vical inc (VICL) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $821.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $292.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $344.8K
Vice President of Vaccine Research
Total Annual Compensation: $337.8K
Compensation as of Fiscal Year 2014.

vical inc (VICL) Key Developments

Vical Incorporated - Special Call

To discuss the results of the trial

Vical Incorporated Reports Top-Line Results from Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine

Vical Incorporated announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD + UL46) vaccine, each formulated with Vical'sproprietary Vaxfectin® adjuvant. The top-line analysis compared pre-vaccination measurements for each arm with those taken during the swabbing period in months 2 and 3 following the last vaccine dose. Neither the monovalent nor bivalent vaccine met the primary endpoint. On prospectively defined secondary endpoints, the bivalent vaccine achieved statistically significant reductions in the rate of genital lesions (-51%, p = 0.0037) and viral load from positive swabs (-0.39 log10, p = 0.0008) versus baseline. Both the monovalent and bivalent vaccines were generally well tolerated. Safety data have been reviewed throughout the trial by an independent safety monitoring board, and no grade 4 adverse events or serious adverse events related to vaccination have been observed.

Vical Incorporated Mulls Acquisitions

Vical Incorporated (NasdaqGS:VICL) is seeking acquisitions. Vical Incorporated has filed a Shelf Registration in the amount of $100.00 million. Vical Incorporated said it will use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses, and potential acquisitions of companies and technologies that complement our business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $0.70 USD +0.0149

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $6.68 USD -0.20
GenVec Inc $2.04 USD -0.05
Inovio Pharmaceuticals Inc $7.92 USD -0.22
Peregrine Pharmaceuticals Inc $1.30 USD +0.01
Transgene SA €3.76 EUR -0.04
View Industry Companies
 

Industry Analysis

VICL

Industry Average

Valuation VICL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.